RIFAXIMIN
Total Payments
$809,231
Transactions
2,016
Doctors
59
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $390,274 | 1,848 | 35 |
| 2017 | $418,957 | 168 | 29 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $743,461 | 1,900 | 91.9% |
| Consulting Fee | $60,365 | 34 | 7.5% |
| Food and Beverage | $4,732 | 75 | 0.6% |
| Travel and Lodging | $672.56 | 7 | 0.1% |
Payments by Type
Research
$743,461
1,900 transactions
General
$65,770
116 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease | Bausch Health US, LLC | $233,985 | 0 |
| A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, MULTIREGIONAL, ONE YEAR STUDY TO ASSESS THE EFFICACY AND SAFETY OF TWICE DAILY ORAL RIFAXIMIN DELAYED RELEASE TABLETS FOR INDUCTION OF CLINICAL REMISSION WITH ENDOSCOPIC RESPONSE AT 16 WEEKS FOLLOWED BY CLINICAL AND ENDOSCOPIC REMISSION AT 52 WEEKS IN SUBJECTS WITH ACTIVE MODERATE CROHN'S DISEASE | Valeant Pharmaceuticals North America LLC | $133,191 | 2 |
| IISRIF1116Mathur | Valeant Pharmaceuticals North America LLC | $100,000 | 1 |
| IISRIF035Bajaj and Sartor | Valeant Pharmaceuticals North America LLC | $70,041 | 1 |
| A Randomized Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Dispersion SSD Tablets Plus Lactulose and Rifaximin Extended Intestinal Release EIR Tablets Plus Lactulose For the Treatment of Overt Hepatic Encephalopathy OHE. | Bausch Health US, LLC | $31,375 | 3 |
| IISRIF027Saito-Loftus | Valeant Pharmaceuticals North America LLC | $29,635 | 1 |
| 2018-3341 Fuchs | Bausch Health US, LLC | $23,660 | 1 |
| A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, MULTIREGIONAL, ONE YEAR STUDY TO ASSESS THE EFFICACY AND SAFETY OF TWICE DAILY ORAL RIFAXIMIN DELAYED RELEASE TABLETS FOR INDUCTION OF CLINICAL REMISSION WITH ENDOSCOPIC RESPONSE AT 16 WEEKS FOLLOWED BY CLINICAL AND ENDOSCOPIC REMISSION AT 52 WEEKS IN SUBJECTS WITH ACTIVE MODERATE CROHNS DISEASE | Valeant Pharmaceuticals North America LLC | $20,896 | 0 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy | Bausch Health US, LLC | $16,259 | 0 |
| IIS- Rif2288 Oneto | Valeant Pharmaceuticals North America LLC | $15,812 | 1 |
| A Phase 1, Open-Label, Randomized, Parallel, Multiple-Dose Study to Assess the Pharmacokentics of Two Rifaximin Formulations in Healthy Subjects | Bausch Health US, LLC | $14,170 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF RIFAXIMIN 550 MG IN SUBJECTS WITH SEVERE HEPATIC IMPAIRMENT AND OVERT HEPATIC ENCEPHALOPATHY | Valeant Pharmaceuticals North America LLC | $9,952 | 0 |
| A Multicenter, Randomized, Open-Label, Active-Controlled, Trial To Evaluate The Safety And Efficacy Of Rifaximin 550 Mg With And Without Lactulose In Subjects With A History Of Recurrent Overt Hepatic Encephalopathy | Bausch Health US, LLC | $8,920 | 0 |
| A Phase 4, Open-Label Study to Evaluate the Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy Subjects and Subjects with Severe Hepatic Impairment | Bausch Health US, LLC | $8,200 | 0 |
| IISRIF028 Sigal | Bausch Health US, LLC | $7,800 | 1 |
| A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients with Active Rheumatoid Arthritis with Inadequate Response to Disease-Modifying Anti-rheumatic Drugs. | Bausch Health US, LLC | $7,495 | 0 |
| A STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF ESCALATING DOSES OF SAN-300 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS. | Valeant Pharmaceuticals North America LLC | $7,386 | 0 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF RIFAXIMIN SOLUBLE SOLID DISPERSION SSD TABLETS FOR THE PREVENTION OF COMPLICATIONS IN SUBJECTS WITH EARLY DECOMPENSATED LIVER CIRRHOSIS | Valeant Pharmaceuticals North America LLC | $2,000 | 0 |
| A MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF RIFAXIMIN 550 MG WITH AND WITHOUT LACTULOSE IN SUBJECTS WITH A HISTORY OF RECURRENT OVERT HEPATIC ENCEPHALOPATHY | Valeant Pharmaceuticals North America LLC | $1,950 | 0 |
| A Phase 1, Open-Label, Randomized, Crossover Study to Evaluate the Pharmacokinetics and Relative Bioavailability of Rifaximin From Two Formulations of Xifaxin 550 mg Tablets and the Dose Proportionality of Xifaxin 200, 400 and 600 mg in Health Subjects | Bausch Health US, LLC | $734.38 | 4 |
Top Doctors Receiving Payments for RIFAXIMIN
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Southlake, TX | $412,287 | 1,843 |
| , M.D | Endocrinology, Diabetes & Metabolism | Los Angeles, CA | $100,000 | 1 |
| , MD | Gastroenterology | Chapel Hill, NC | $70,041 | 1 |
| , MD | Gastroenterology | Sioux Falls, SD | $32,947 | 18 |
| , M.D | Gastroenterology | Rochester, MN | $29,635 | 1 |
| , M.D | Internal Medicine | Richmond, VA | $23,660 | 1 |
| , M.D | Internal Medicine | Los Angeles, CA | $17,875 | 6 |
| , M.D | Gastroenterology | New York, NY | $15,812 | 1 |
| , M.D | Pediatrics | Camden, NJ | $14,806 | 10 |
| , M.D | Family Medicine | Mesa, AZ | $14,170 | 1 |
| , MD | Gastroenterology | Tupelo, MS | $9,000 | 3 |
| , MD | Internal Medicine | New York, NY | $7,800 | 1 |
| , M.D | Gastroenterology | Los Angeles, CA | $5,084 | 8 |
| , MD | Gastroenterology | Los Angeles, CA | $5,000 | 1 |
| , MD, MPH, FACP | Hepatology | Philadelphia, PA | $4,500 | 2 |
| , MD | Gastroenterology | Los Angeles, CA | $3,766 | 6 |
| , PH.D; M.D | Gastroenterology | Lebanon, NH | $3,766 | 6 |
| , MD | Gastroenterology | Mobile, AL | $3,766 | 6 |
| , MD | Gastroenterology | Los Angeles, CA | $3,712 | 5 |
| , MD PHD | Internal Medicine | Augusta, GA | $3,182 | 5 |
| , MD | Gastroenterology | Creve Coeur, MO | $2,266 | 4 |
| , MD | Gastroenterology | Los Angeles, CA | $1,948 | 4 |
| , M.D | Gastroenterology | Houston, TX | $1,930 | 4 |
| , MD | Gastroenterology | Los Angeles, CA | $1,900 | 3 |
| , M.D | Infectious Disease | Houston, TX | $1,900 | 3 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $809,231
- Total Doctors 59
- Transactions 2,016
About RIFAXIMIN
RIFAXIMIN is a drug associated with $809,231 in payments to 59 healthcare providers, recorded across 2,016 transactions in the CMS Open Payments database. The primary manufacturer is Valeant Pharmaceuticals North America LLC.
Payment data is available from 2017 to 2018. In 2018, $390,274 was paid across 1,848 transactions to 35 doctors.
The most common payment nature for RIFAXIMIN is "Unspecified" ($743,461, 91.9% of total).
RIFAXIMIN is associated with 20 research studies, including "A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease" ($233,985).